Showing results (91-100 of 99) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 99 results.
European Urology|December 15, 2015
The Proteome of Primary Prostate CancerDiego Iglesias-Gato, Pernilla Wikström, Stefka Tyanova, et al.
The Lancet. Oncology|February 8, 2026
Ultra-hypofractionated versus conventionally fractionated radiotherapy for localised prostate cancer (HYPO-RT-PC): 10-year outcomes of an open-label, randomised, phase 3, non-inferiority trialPer Nilsson, Adalsteinn Gunnlaugsson, Lars Beckman, et al.
The Lancet. Oncology|January 14, 2021
Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trialPer Fransson, Per Nilsson, Adalsteinn Gunnlaugsson, et al.
Lancet (London, England)|June 23, 2019
Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trialAnders Widmark, Adalsteinn Gunnlaugsson, Lars Beckman, et al.
Nuclear Medicine Communications|August 24, 2023
Histopathology-validated lesion detection rates of clinically significant prostate cancer with mpMRI, [ 68 Ga]PSMA-11-PET and [ 11 C]Acetate-PETKristina Sandgren, Sara N Strandberg, Joakim H Jonsson, et al.
Physics and Imaging in Radiation Oncology|September 17, 2024
Histopathology-validated gross tumor volume delineations of intraprostatic lesions using PSMA-positron emission tomography/multiparametric magnetic resonance imagingJosefine Grefve, Karin Söderkvist, Adalsteinn Gunnlaugsson, et al.
Acta Oncologica (Stockholm, Sweden)|June 24, 2024
Accuracy of gross tumour volume delineation with [68Ga]-PSMA-PET compared to histopathology for high-risk prostate cancerMaryam Zarei, Elin Wallsten, Josefine Grefve, et al.
The Lancet. Oncology|May 20, 2014
Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trialOliver Sartor, Robert Coleman, Sten Nilsson, et al.
European Urology|July 15, 2017
Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer TrialChristopher C Parker, Robert E Coleman, Oliver Sartor, et al.
Pageof 10